非小细胞肺癌，放疗系列研究汇总（不可手术Ⅲ期）

参考文献

[1]Dillman RO, Herndon J,Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer:seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J NatlCancer Inst. 1996 Sep 4;88(17):1210-5. doi: 10.1093/jnci/88.17.1210.

[2]Sause W, Kolesar P,Taylor S IV, et al. Final results of phase III trial in regionally advancedunresectable non-small cell lung cancer: Radiation Therapy Oncology Group,Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000Feb;117(2):358-64. doi: 10.1378/chest.117.2.358.

[3]Furuse K, Fukuoka M,Kawahara M, et al. Phase III study of concurrent versus sequential thoracicradiotherapy in combination with mitomycin, vindesine, and cisplatin inunresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999Sep;17(9):2692-9. doi: 10.1200/JCO.1999.17.9.2692.

[4]Curran WJ Jr, Paulus R,Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage IIInon-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl CancerInst. 2011 Oct 5;103(19):1452-60. doi: 10.1093/jnci/djr325.

[5]Aupérin A, Le Péchoux C,Rolland E, et al. Meta-analysis of concomitant versus sequentialradiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol.2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543.

[6]Miller ED, Fisher JL,Haglund KE, et al The Addition of Chemotherapy to Radiation Therapy ImprovesSurvival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. JThorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135.

[7]Sause W, Kolesar P,Taylor S IV, et al. Final results of phase III trial in regionally advancedunresectable non-small cell lung cancer: Radiation Therapy Oncology Group,Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000Feb;117(2):358-64. doi: 10.1378/chest.117.2.358.

[8]Mauguen A, Le Péchoux C,Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lungcancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug1;30(22):2788-97. doi: 10.1200/JCO.2012.41.6677.

[9]Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol. 2007 May 1;25(13):1698-704. doi: 10.1200/JCO.2006.07.3569.

[10]Albain KS, Crowley JJ, Turrisi AT 3rd, etal. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stageIIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study,SWOG 9019. J Clin Oncol. 2002 Aug 15;20(16):3454-60. doi:10.1200/JCO.2002.03.055.

[11]Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008 May 20;26(15):2450-6. doi: 10.1200/JCO.2007.14.4824.

[12]Ready N, Jänne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J Thorac Oncol. 2010 Sep;5(9):1382-90. doi: 10.1097/JTO.0b013e3181eba657. 

[13]Ahn JS, Ahn YC, Kim JH, etal. Multinational Randomized Phase III Trial With or Without ConsolidationChemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation inInoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. J Clin Oncol.2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130.

[14]Bradley JD, Paulus R, Komaki R, et al.Standard-dose versus high-dose conformal radiotherapy with concurrent andconsolidation carboplatin plus paclitaxel with or without cetuximab forpatients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): arandomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015Feb;16(2):187-99. doi: 10.1016/S1470-2045(14)71207-0.

[15] Bradley JD, Hu C, Komaki RR, et al. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 Mar 1;38(7):706-714.

[16]Schiller JH, HarringtonD, Belani CP, et al. Comparison of four chemotherapy regimens for advancednon-small-cell lung cancer. N Engl J Med. 2002 Jan 10;346(2):92-8. doi:10.1056/NEJMoa011954.

[17]Yamamoto N, Nakagawa K,Nishimura Y, etal. Phase III study comparing second- and third-generationregimens withconcurrent thoracic radiotherapy in patients with unresectablestage IIInon-small-cell lung cancer: West Japan Thoracic Oncology GroupWJTOG0105[J]. JClin Oncol. 2010,28(23):3739-45.

[18]Senan S, Brade A, Wang LH, et al.PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin orEtoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by ConsolidationChemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer. J ClinOncol. 2016 Mar 20;34(9):953-62. doi: 10.1200/JCO.2015.64.8824.

[19]Liang J, Bi N, Wu S, et al.Etoposide and cisplatin versus paclitaxel and carboplatin with concurrentthoracic radiotherapy in unresectable stage III non-small cell lung cancer: amulticenter randomized phase III trial. Ann Oncol. 2017 Apr 1;28(4):777-783.doi: 10.1093/annonc/mdx009.

[20]Antonia SJ et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med 2017 Sep 8; [e-pub]. （https://dx.doi.org/10.1056/NEJMoa1709937）

[21]Antonia SJ et al. Overall survival with durvalumab after chemoradiotherapy in stage Ⅲ NSCLC. N Engl J Med 2018 Sep 25; [e-pub]. (https://doi.org/10.1056/NEJMoa1809697)

[22]Jhanelle E Gray JE, Villegas A, Daniel D, et al. Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC. Journal of Thoracic Oncology. 2020;15(2):288-293.